Hosted on MSN1mon
Bio-Thera signs US deal with Intas for golimumab biosimilarAccord BioPharma US president Chrys Kokino stated: “Our exclusive commercialisation agreement with Bio-Thera strengthens our biosimilar pipeline, a vital component of our US growth strategy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback